The Pharmacy Times® Mental Health Resource Center is a comprehensive resource for clinical news and expert insights on conditions that affect mood, thinking, and behavior, including clinical depression, bipolar disorder, schizophrenia, anxiety, and post-traumatic stress disorder.
November 20th 2024
Lenora Newsome, PD, president of the National Association of Boards of Pharmacy, explores how pharmacists can support mental health.
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Exploring Therapeutic Advances for Bipolar Disorder With Mixed Features and Anxious Distress: An Update for Ph...
2.0 Credits / Neurology, Psychiatry
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Prescription Digital Therapeutics in Schizophrenia: A Managed Care Perspective on Advancements
2.0 Credits / Psychiatry
View More
Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia
3.0 Credits / Psychiatry
View More
Lithium and Libido: Few Studies, Some Problems in Bipolar Patients
February 12th 2015Patients who take antipsychotic and antidepressant medications frequently experience sexual side effects, necessitating dose adjustments. Lithium is a cornerstone treatment for many patients with bipolar disorder, but few studies have investigated its effect on sexual function.
Read More
Which Atrial Fibrillation Patients Are Most Likely to Misreport Symptoms?
January 30th 2015A primary goal of managing atrial fibrillation is relief of symptoms that include dizziness, fatigue, palpitations, shortness of breath, and chest pain. Yet, it is symptomless in up to one-third of patients.
Read More
Actavis Resubmits Cariprazine Approval Application to FDA
January 8th 2015The FDA has acknowledged receipt of Actavis's resubmitted New Drug Application for its investigational atypical antipsychotic, cariprazine, which is indicated for the treatment of patients with schizophrenia and manic or mixed episodes associated with bipolar I disorder.
Read More
Long-Term Bipolar Treatment Maintains Cognitive Health
January 6th 2015Cognitive impairment in patients with bipolar disorder is a growing research priority. Long suspected to be restricted to those with symptomatic illness, cognitive impairment has also been found in patients who are well controlled and euthymic.
Read More
Adherence Issues with Antidepressants in Bipolar Patients
December 25th 2014Bipolar patients are among the most difficult to treat, in part because mania is alluring and in part because they are often poor historians. As with any patient who must take medication for a chronic condition, bipolar patients' adherence rates generally decline over time. About two-thirds of bipolar patients take more than 1 medication for this condition, and an antidepressant is often one component of the drug regimen.
Read More
Bipolar Patients at High Risk for Self-Harm Recurrence
December 5th 2014Up to 60% of patients diagnosed with bipolar disorder cause harm to themselves at least once throughout their lifetimes, and at least 5% of them commit suicide. Nevertheless, few prospective studies have examined self-harm in BPD patients specifically.
Read More
Ethnic Minorities Still Receiving Inferior Mental Health Treatment, Says APA Journal
December 5th 2014Primary care that includes mental health screenings and treatments that take into account a patient's language and cultural background can help address mental health care disparities among ethnic minorities.
Read More
FDA Grants Priority Review to Bipolar Indication for Schizophrenia Drug
November 14th 2014Actavis's supplemental New Drug Application for asenapine to treat manic or mixed episodes related to bipolar disorder in pediatric patients has been accepted by the FDA and given priority review status.
Read More